In contrast, in NSCLC patients treated by other therapies, PD‐L1+ CTCs predicted worse survival (PFS: HR = 1.96, 95% CI 0.91–4.22, p = 0.086; OS: HR = 3.34, 95% CI 1.68–6.64, p = 0.001). Here, CD274 is linked to non-small cell lung carcinoma.